PEPTIDEREPORT

Best for Stress, anxiety, and sleep-related research

Best Peptides for Stress and Anxiety Research

Online discussions often describe Selank, Semax, and DSIP as established solutions for anxiety, focus, or sleep. The source record is much narrower: Russian regulatory use and publications for Selank and Semax, plus older mixed sleep studies for DSIP. This page ranks evidence depth and replication, not popularity.

Last reviewed 2026-07-10 Next review 2026-08-10 7 sources
# Compound Evidence level Why it's listed
1 Selank
Research watch — preclinical and limited Russian clinical use Limited clinical use and peer-reviewed mechanistic research; weak independent replication The most directly anxiety-oriented compound in this group, with Russian pharmaceutical use and published mechanistic literature but little independent replication.
2 Semax
Regulatory watch Russian clinical publications and preclinical research A Russian-registered peptide discussed for attention and stress resilience, with a larger cognitive framing than direct anxiety evidence.
3 DSIP
Regulatory watch Older limited clinical studies and preclinical research Directly associated with sleep research, but supported mainly by older small studies with mixed and inconclusive findings.

Selank

Selank

The most directly anxiety-oriented compound in this group, with Russian pharmaceutical use and published mechanistic literature but little independent replication.

Evidence level: Limited clinical use and peer-reviewed mechanistic research; weak independent replication

Regulatory status: Registered in Russia; not FDA-approved

Selank is a tuftsin-derived peptide registered in Russia for anxiety-related use. Publications discuss GABA-related mechanisms, immune signaling, and functional-connectivity findings, but much of the evidence comes from Russian research groups and lacks large independent clinical replication.

Semax

Semax

A Russian-registered peptide discussed for attention and stress resilience, with a larger cognitive framing than direct anxiety evidence.

Evidence level: Russian clinical publications and preclinical research

Regulatory status: Registered in Russia; not FDA-approved and under regulatory watch

Semax is an ACTH-derived peptide registered in Russia. Russian-language publications describe cognitive and attention effects, while experimental studies compare its neural-network effects with Selank. Independent Western clinical replication is lacking.

DSIP

DSIP

Directly associated with sleep research, but supported mainly by older small studies with mixed and inconclusive findings.

Evidence level: Older limited clinical studies and preclinical research

Regulatory status: Not FDA-approved; regulatory watch

Delta sleep-inducing peptide was studied in early human and animal sleep research. Historical studies reported variable effects, and modern clinical evidence has not established a reliable sleep treatment benefit.

Editorial note

None of these peptides is FDA-approved for anxiety, stress, or sleep treatment in the United States. Russian registration and small historical studies do not establish general efficacy or safety.

Sources on this page

Source records are stored in the repo and linked from this page.

Semax: cognitive and attention effects in clinical and preclinical studies

PubMed / NCBI · Peer reviewed · 2006-01-01 · accessed 2026-07-03

Russian-language clinical and preclinical publications on Semax (a heptapeptide ACTH analog) describing cognitive and attention-enhancing effects. Studies are primarily from Russian institutions and lack independent Western replication.

Effects of DSIP on sleep in humans — clinical sleep studies

PubMed / NCBI · Peer reviewed · 1984-01-01 · accessed 2026-07-03

Clinical studies of delta sleep-inducing peptide (DSIP) in human sleep, dating to the 1970s-1980s, with mixed and inconclusive results. The DSIP clinical literature is old and has not been advanced with modern trials.